Nirmatrelvir-resistant SARS-CoV-2 is efficiently transmitted in female Syrian hamsters and retains partial susceptibility to treatment
Abstract The SARS-CoV-2 main protease (3CLpro) is one of the promising therapeutic targets for the treatment of COVID-19. Nirmatrelvir is the first 3CLpro inhibitor authorized for treatment of COVID-19 patients at high risk of hospitalization. We recently reported on the in vitro selection of SARS-C...
Guardat en:
| Autors principals: | , , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Nature Portfolio
2023-04-01
|
| Col·lecció: | Nature Communications |
| Accés en línia: | https://doi.org/10.1038/s41467-023-37773-6 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|